Acknowledgement

ITOC3_Banner_695x90

Conference Committee

The ITOC3 Organising Committee wishes to gratefully acknowledge and thank the conference presidents and the scientific committee for developing and supporting the 3rd Immunotherapy of Cancer Conference.

Conference Presidents

  • Alexander M.M. Eggermont (France)
  • Howard L. Kaufman (USA)
  • Volkmar Nüssler (Germany)

Scientific Committee

  • Heinz Zwierzina (Austria) – Scientific Programme Committee Chair
  • Paolo A. Ascierto (Italy)
  • Lisa Butterfield (USA)
  • Angus Dalgleish (United Kingdom)
  • Stefan Endres (Germany)
  • Leif Hakansson (Sweden)
  • Robert Hawkins (United Kingdom)
  • Samir Khleif (United States)
  • Sebastian Kobold (Germany)
  • José Saro (Switzerland)
  • Barbara Seliger (Germany)
  • Wenru Song (USA)
  • Christoph Zielinski (Austria)

Sponsors

We thank all ITOC3 sponsors

The ITOC3 Organising Committee wishes to gratefully acknowledge our sponsors for supporting the 3rd Immunotherapy of Cancer Conference.

Platinum sponsors

bms301 - BMS Logo Blue JPG Bristol-Myers Squibb
Celgene_Full_Color Celgene
RocheLogo Roche

Silver sponsor

www.lillyoncology.com/ Lilly Oncology

Sponsor and Exhibitor Profiles

  • Affymetrix
    Affymetrix’ tools for cancer research enable whole-genome analysis through single-gene validation across diverse sample types including FFPE. Their solutions for expression, miRNA, genotyping, flow cytometry, and molecular biology reagents provide an integrated view of the gene -protein -cell, for faster translation of discoveries to treatments. For more information, please visit: http://www.affymetrix.com/estore/
  • AstraZeneca
    AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas – respiratory, inflammation, autoimmune disease, cardiovascular and metabolic disease and oncology – as well as in infection and neuroscience. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
  • BristolMeyersSquibb
    Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Our focus for the future of cancer care is on Immuno-Oncology. We have a comprehensive clinical portfolio of investigational and approved Immuno-Oncology agents, many of which were discovered and developed by our scientists. For more information about Bristol-Myers Squibb, visit: www.b-ms.de
  • Celgene
    Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. We seek to deliver truly innovative and life-changing drugs for our patients through the discovery, development, and commercialization of products for cancer and other severe, immune, inflammatory conditions. Celgene employs more than 5,300 employees worldwide.
  • CellGenix
    CellGenix is a premium supplier of high-quality ancillary products, reagents and tools for cell therapy and regenerative medicine. Our cytokines and serum-free media are manufactured in accordance with the relevant cGMP, Ph. Eur., USP, and ICH guidelines. CellGenix offers a comprehensive product portfolio for the seamless transition from research to commercialisation.
  • Definiens
    Definiens is the pioneering provider of Tissue Phenomics® solutions for biomarker and companion diagnostics development and commercialization.  Definiens’ technology empowers smarter tissue-based diagnostics by leveraging quantitative tissue readouts and other big data sources. By enabling the development of powerful and precise assays for patient stratification and clinical trial enrollment, Definiens aims to dramatically improve patient outcomes. Definiens’ Tissue Phenomics approach was awarded the 2013 Frost and Sullivan Company of the Year Award for Global Tissue Diagnostics and Pathology Imaging. For more information, please visit: www.definiens.com
  • Essen Bioscience
    The IncuCyte® Real-Time Quantitative Live-Cell Analysis System, designed by Essen BioScience, Inc. is the first system to enable quantification of cell behaviour over time (from hours to weeks) by automatically gathering and analysing images around the clock within a stand incubator. The IncuCyte® System provides insight into active biological processes in real-time and allows researchers to gather more information from assays they conduct in a faster and automated way that single-point or endpoint assays can’t achieve. In addition to the IncuCyte® instrumentation, Essen BioScience also provides reagents and analysis software which enable researchers to perform real-time, quantitative live cell analysis and evaluate a wide variety of cellular processes over time within a standard laboratory incubator.
  • HTG Molecular Diagnostics
    Headquartered in Tucson, Arizona, HTG’s mission is to empower precision medicine at the local level. In 2013 the company commercialized its HTG Edge instrument platform and a portfolio of RNA assays that leverage HTG’s proprietary nuclease protection chemistry. HTG’s product offerings have since expanded to include its HTG EdgeSeq product line, which automates sample and targeted library preparation for next-generation sequencing. Additional information is available at: www.htgmolecular.com
  • Macopharma: Your Cell Therapy Partner
    Macopharma has developed a wide range of products in the fields of cell & tissue therapy, regenerative medicine and transplantation. The biotherapy range of products provides solutions for every step of the cellular therapy process from collection, processing, expansion and cryopreservation of stem cells, up to the treatment and transplantation of cells or organs to patients.
  • Miltenyi Biotech
    Miltenyi Biotec provides products that advance biomedical research and cellular therapy. Our innovative tools support research from basic research to translational research to clinical application. Our more than 25 years of expertise includes immunology, stem cell biology, neuroscience, and cancer.  Miltenyi Biotec has more than 1,500 employees in 25 countries.
  • Nanostring Technologies
    NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company’s nCounter® Analysis System, which has been employed in basic and translational research and cited in 500 peer review publications, has also now been applied to diagnostic use with the nCounter Dx Analysis System and uses the nCounter-based Prosigna™ Breast Cancer Prognostic Gene Signature Assay.
  • Perkin Elmer
    PerkinElmer’s Phenoptics™ Quantitative Pathology Solutions for cancer immunology and immunotherapy research is a unique workflow, which includes multiplexed staining reagents and methodologies, instrumentation with unique channel-separation technology, and advanced image analysis software that can be trained to phenotype cells and measure checkpoint, activation and functional markers between cells and within the tumour microenvironment.
  • ProQinase
    ProQinase is a leading service provider for anti-cancer drug development. Apart from biochemical and cell-based assay services, the company offers a broad range of mouse tumour models including subcutaneous, orthotopic and metastasis models. Our immuno-oncology platform comprises several syngeneic models and supporting immunoassays for their analysis. Our strengths are custom-tailored solutions for the testing of your drug or immunotherapeutic.
  • Roche
    Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. For more information, please visit: www.roche.com

Satellite Symposia

  •  ‘Broadening the horizon of Immuno-Oncology in 2016: What Happens at Bench and Bedside?’ – Bristol-Meyers Squibb
  • ‘Advancing Immunotherapy in Lymphoid Malignancies’ – Celgene
  • ‘Enhancing Cancer Immunotherapy: A Dialogue Between the Laboratory and the Clinic’ – Roche